Jefferies Group LLC Reaffirms Hold Rating for Cempra, Inc. (CEMP)
Cempra, Inc. (NASDAQ:CEMP)‘s stock had its “hold” rating reiterated by Jefferies Group LLC in a research note issued on Thursday. They currently have a $3.00 price target on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential downside of 4.76% from the company’s previous close.
Several other analysts also recently issued reports on CEMP. ValuEngine downgraded shares of Cempra from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Stifel Nicolaus reaffirmed a “hold” rating and issued a $4.00 price target on shares of Cempra in a report on Thursday, August 10th. Roth Capital downgraded shares of Cempra from a “buy” rating to a “neutral” rating and reduced their price target for the company from $8.00 to $4.00 in a report on Thursday, August 10th. Finally, Zacks Investment Research raised shares of Cempra from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Friday, August 11th. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Cempra currently has an average rating of “Hold” and a consensus price target of $10.00.
Shares of Cempra (NASDAQ CEMP) traded up 0.806% during mid-day trading on Thursday, hitting $3.125. 550,119 shares of the stock were exchanged. The stock’s market cap is $164.08 million. Cempra has a one year low of $2.55 and a one year high of $26.95. The company has a 50-day moving average of $3.33 and a 200 day moving average of $3.82.
Cempra (NASDAQ:CEMP) last announced its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The company had revenue of $0.86 million for the quarter, compared to the consensus estimate of $3.58 million. During the same quarter in the prior year, the firm earned ($0.51) earnings per share. The company’s revenue for the quarter was down 74.9% compared to the same quarter last year. On average, equities analysts predict that Cempra will post ($1.01) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Reaffirms Hold Rating for Cempra, Inc. (CEMP)” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/14/jefferies-group-llc-reaffirms-hold-rating-for-cempra-inc-cemp.html.
A number of large investors have recently bought and sold shares of CEMP. Pennsylvania Trust Co purchased a new position in Cempra during the second quarter worth approximately $7,784,000. Renaissance Technologies LLC raised its stake in Cempra by 175.0% during the first quarter. Renaissance Technologies LLC now owns 1,680,500 shares of the biotechnology company’s stock worth $6,302,000 after purchasing an additional 1,069,300 shares during the period. Dimensional Fund Advisors LP raised its stake in Cempra by 1,279.1% during the second quarter. Dimensional Fund Advisors LP now owns 753,402 shares of the biotechnology company’s stock worth $3,466,000 after purchasing an additional 698,771 shares during the period. Bogle Investment Management L P DE raised its stake in Cempra by 607.0% during the first quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock worth $2,660,000 after purchasing an additional 609,168 shares during the period. Finally, TIAA CREF Investment Management LLC raised its stake in Cempra by 61.6% during the second quarter. TIAA CREF Investment Management LLC now owns 461,451 shares of the biotechnology company’s stock worth $2,123,000 after purchasing an additional 175,874 shares during the period. 49.76% of the stock is currently owned by institutional investors.
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.